NASDAQ:NMTR 9 Meters Biopharma (NMTR) Stock Price, News & Analysis → Must-See: Elon’s New Invention is Absolutely Insane (From InvestorPlace) (Ad) Free NMTR Stock Alerts $0.07 -0.05 (-42.97%) (As of 07/25/2023) Add Compare Share Share Today's Range$0.07▼$0.1150-Day Range$0.00▼$0.0252-Week Range$0.07▼$6.56Volume9.96 million shsAverage Volume315,915 shsMarket Capitalization$1.04 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsHeadlinesInsider TradesSocial MediaStock AnalysisAnalyst ForecastsHeadlinesInsider TradesSocial Media Get 9 Meters Biopharma alerts: Email Address Ad The Freeport SocietyNext President (Not Trump. Not Biden.)Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be Trump.Click here to see why it will be ______ _________. About 9 Meters Biopharma Stock (NASDAQ:NMTR)9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.Read More NMTR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NMTR Stock News HeadlinesDecember 14, 2023 | bbc.comEnergy firms likely to miss smart meter deadline, warns Which?November 8, 2023 | bizjournals.comDeal reached to sell some assets of bankrupt Raleigh firmNovember 7, 2023 | finance.yahoo.com9 Meters Biopharma, Inc. (NMTRQ)October 17, 2023 | investing.com9 Meters Biopharma Inc (NMTRQ)August 16, 2023 | fool.com9 Meters Biopharma (OTC: NMTR.Q)July 18, 2023 | bizjournals.comRaleigh firm joins worrying trend of bankruptcies for drugmakersJuly 18, 2023 | reuters.comDrug developer 9 Meters Biopharma files for bankruptcy protectionJuly 18, 2023 | finance.yahoo.comWhy Are 9 Meters Biopharma Shares Nosediving Today?May 30, 2023 | bizjournals.comTemperato resigns as CEO of Raleigh drugmakerMay 30, 2023 | finance.yahoo.com9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel SyndromeMay 28, 2023 | fool.com9 Meters Biopharma (NASDAQ: NMTR)May 25, 2023 | uk.finance.yahoo.comNMTR - 9 Meters Biopharma, Inc.May 19, 2023 | msn.comCitigroup Maintains 9 Meters Biopharma (NMTR) Neutral RecommendationMay 15, 2023 | finance.yahoo.com9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023April 5, 2023 | finance.yahoo.com9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for ObesityMarch 30, 2023 | bizjournals.comWhy this Raleigh pharma just cut half its workforceMarch 28, 2023 | finance.yahoo.com9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2022March 25, 2023 | seekingalpha.comNMTR 9 Meters Biopharma, Inc.March 22, 2023 | benzinga.com9 Meters Biopharma Stock (NASDAQ:NMTR), Guidance and ForecastMarch 16, 2023 | bizjournals.comRaleigh pharma raises $5M as phase 3 study beginsMarch 15, 2023 | finance.yahoo.com9 Meters Biopharma Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesMarch 14, 2023 | finance.yahoo.com9 Meters Biopharma Announces $5 Million Registered Direct Offering Priced at-the-Market Under Nasdaq RulesMarch 7, 2023 | finance.yahoo.com9 Meters Biopharma to Present at the Oppenheimer 33rd Annual Healthcare ConferenceFebruary 23, 2023 | theguardian.comSuppliers told to remove prepayment meters that were wrongly force-fittedJanuary 31, 2023 | finance.yahoo.com9 Meters Biopharma to Present at the 2023 BIO CEO & Investor ConferenceSee More Headlines Receive NMTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 9 Meters Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:NMTR CUSIPN/A CIK1551986 Webwww.9meters.com Phone(919) 275-1933FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-43,770,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-584.97% Return on Assets-159.45% Debt Debt-to-Equity RatioN/A Current Ratio0.59 Quick Ratio0.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.19 per share Price / Book0.38Miscellaneous Outstanding Shares14,336,000Free Float13,992,000Market Cap$1.04 million OptionableNo Data Beta1.36 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMs. Bethany Sensenig C.M.A. (Age 47)M.B.A., Interim CEO & CFO Comp: $525.59kDr. Peter H. R. Green M.D.Clinical & Scientific Advisor and ConsultantMr. Joseph A. Murray M.D.Clinical & Scientific Advisor and ConsultantDr. Ciaran P. Kelly M.D.Clinical & Scientific Advisor and ConsultantDr. Elena Verdu M.D.Ph.D., Clinical & Scientific Advisor and ConsultantMr. Markku Mäki M.D.Ph.D., Clinical & Scientific Advisor and ConsultantDr. William J. Sandborn M.D. (Age 60)Ph.D., Clinical & Scientific Advisor and Consultant Dr. Roger Liddle M.D.Clinical & Scientific Advisor and ConsultantDr. Anthony J. Dimarino Jr.Clinical & Scientific Advisor and ConsultantDr. Brian Gordon Feagan FRCPCM.D., M.P.H., Clinical & Scientific Advisor and ConsultantMore ExecutivesKey CompetitorsPolarityTENASDAQ:PTEIQEiger BioPharmaceuticalsNASDAQ:EIGRBone BiologicsNASDAQ:BBLGEvelo BiosciencesNASDAQ:EVLOEvofem BiosciencesNASDAQ:EVFMView All Competitors NMTR Stock Analysis - Frequently Asked Questions Should I buy or sell 9 Meters Biopharma stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 9 Meters Biopharma in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" NMTR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NMTR, but not buy additional shares or sell existing shares. View NMTR analyst ratings or view top-rated stocks. How were 9 Meters Biopharma's earnings last quarter? 9 Meters Biopharma, Inc. (NASDAQ:NMTR) announced its earnings results on Monday, November, 15th. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.74) by $0.26. When did 9 Meters Biopharma's stock split? Shares of 9 Meters Biopharma reverse split before market open on Tuesday, October 18th 2022. The 1-20 reverse split was announced on Tuesday, October 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of 9 Meters Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other 9 Meters Biopharma investors own include Acasti Pharma (ACST), Miragen Therapeutics (MGEN), Bionano Genomics (BNGO), Evofem Biosciences (EVFM), Outlook Therapeutics (OTLK), Tonix Pharmaceuticals (TNXP), Alibaba Group (BABA), Cellectar Biosciences (CLRB), Pfizer (PFE) and Soleno Therapeutics (SLNO). How do I buy shares of 9 Meters Biopharma? Shares of NMTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NMTR) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarUrgent Nvidia WarningAltimetryShocking: One AI startup's revenue could surge 4,735%Manward PressBill Gates is all about this tiny $2 stockTimothy SykesCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 9 Meters Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
